1. Cancer Clinical Trials A treatment option for cancer patients

2. Today’s standard treatment options are a product of prior research Clinical Trials serve as vehicles of innovation and progress resulting in:  Improved clinical outcomes  Personalized treatment plans which are more effective and less toxic

3. Barriers based in common misconceptions Fear of abuse or exploitation: My patients will be treated like “guinea pigs” if they participate in a clinical trial *Slide content adapted from the Education Network to Advance Cancer Clinical Trials (ENACCT), used with permission.

4. Barriers based in common misconceptions Misunderstanding of the purpose of cancer clinical trials: “Clinical trials are only for patients who have run out of other treatment options” *Slide content adapted from the Education Network to Advance Cancer Clinical Trials (ENACCT), used with permission.

5. Barriers based in common misconceptions Misunderstanding of design/ethics of cancer clinical trials: “My patients may receive a placebo instead of appropriate treatments” *Slide content adapted from the Education Network to Advance Cancer Clinical Trials (ENACCT), used with permission.

6. Clinical Trials provide a good quality option for care Expert panels state that clinical trials provide a high quality treatment option for cancer patients at all stages of the disease continuum  National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: “…the best management of any cancer patient is in a clinical trial.”  Institute of Medicine: “…therapies offered through Cancer Clinical Trials should ideally be considered the preferred treatment choice for physicians and patients, if they are available.” *Slide content from the Education Network to Advance Cancer Clinical Trials (ENACCT), used with permission.

7. Phase III Study Question: Is the agent better than the standard approach? n = 100s-1000s Phase II Study Question: Is the agent effective? n = <100 Phase I Study Question: Is the agent safe? n = 15–20 Phases of Cancer Clinical Trials: *Slide content adapted from the Education Network to Advance Cancer Clinical Trials (ENACCT), used with permission.

8. A call to action Progress is a result of a communal effort that requires a solid partnership between patients and doctors. Each individual physician can participate by: Referring patients to oncologists that conduct clinical trials. Introducing the concept of a clinical trial as a viable treatment option. Providing patients with print information about clinical trials. Encouraging patients to ask their oncologist about clinical trials

9. We are available to answer your questions: [Insert contact information]

10. Reference Education Network to Advance Cancer Clinical Trials (ENACCT): http://www.enacct.org http://www.enacct.org Comis RL, Miller JD, et al. Public attitudes toward participation in cancer clinical trials. J Clin Oncol. 2003;21(5):830-835. National Comprehensive Cancer Network Guidelines: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp http://www.nccn.org/professionals/physician_gls/f_guidelines.asp National Cancer Clinical Trials System for the 21 st Century: Reinvigorating the NCI Cooperative Group Program. Institute of Medicine of the National Academies; 2010. Fenton L, Rigney M, Herbst R. Clinical trial awareness, attitudes, and participation among patients with cancer and oncologists. Commun Oncol. 2009;6:207-213. Comis RL, Miller JD. Cancer clinical trials awareness and attitudes in cancer survivors. Philadelphia (PA): Coalition of Cancer Cooperative Groups; 2005: http://www.cancertrialshelp.org/Icare_content/icMainContent.aspx?int AppMode=19. http://www.cancertrialshelp.org/Icare_content/icMainContent.aspx?int AppMode=19